View in EDS HTML Full Text PDF Full Text

Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Saved in:
Bibliographic Details
Title: Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
Authors: Fricke JG; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland., Westerbergh F; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden., McDougall L; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland., Favaretto C; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland., Christ E; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland.; Division of Endocrinology, University Hospital Basel, Basel, Switzerland., Nicolas GP; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland., Geistlich S; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland., Schmid DE; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland., Borgna F; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland., Fani M; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., Bernhardt P; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.; Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden., van der Meulen NP; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Laboratory of Radiochemistry, PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, Switzerland; and., Müller C; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Wild D; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; damian.wild@usb.ch.; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland.
Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2026 Mar 02; Vol. 67 (3), pp. 416-422. Date of Electronic Publication: 2026 Mar 02.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41381241
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Targeted β<superscript>-</superscript>-Particle Plus Conversion and Auger-Electron Therapy with <superscript>161</superscript>Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fricke+JG%22">Fricke JG</searchLink>; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Westerbergh+F%22">Westerbergh F</searchLink>; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22McDougall+L%22">McDougall L</searchLink>; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Favaretto+C%22">Favaretto C</searchLink>; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.<br /><searchLink fieldCode="AU" term="%22Christ+E%22">Christ E</searchLink>; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland.; Division of Endocrinology, University Hospital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Nicolas+GP%22">Nicolas GP</searchLink>; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Geistlich+S%22">Geistlich S</searchLink>; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schmid+DE%22">Schmid DE</searchLink>; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.<br /><searchLink fieldCode="AU" term="%22Borgna+F%22">Borgna F</searchLink>; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.<br /><searchLink fieldCode="AU" term="%22Fani+M%22">Fani M</searchLink>; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bernhardt+P%22">Bernhardt P</searchLink>; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.; Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22van+der+Meulen+NP%22">van der Meulen NP</searchLink>; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Laboratory of Radiochemistry, PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, Switzerland; and.<br /><searchLink fieldCode="AU" term="%22Müller+C%22">Müller C</searchLink>; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schibli+R%22">Schibli R</searchLink>; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Wild+D%22">Wild D</searchLink>; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; damian.wild@usb.ch.; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220217410%22">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</searchLink> [J Nucl Med] 2026 Mar 02; Vol. 67 (3), pp. 416-422. <i>Date of Electronic Publication: </i>2026 Mar 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Society+of+Nuclear+Medicine%22">Society of Nuclear Medicine </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0217410 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1535-5667 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201615505%22">01615505 </searchLink><i>NLM ISO Abbreviation: </i>J Nucl Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41381241
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2967/jnumed.125.270654
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 416
    Titles:
      – TitleFull: Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fricke JG
      – PersonEntity:
          Name:
            NameFull: Westerbergh F
      – PersonEntity:
          Name:
            NameFull: McDougall L
      – PersonEntity:
          Name:
            NameFull: Favaretto C
      – PersonEntity:
          Name:
            NameFull: Christ E
      – PersonEntity:
          Name:
            NameFull: Nicolas GP
      – PersonEntity:
          Name:
            NameFull: Geistlich S
      – PersonEntity:
          Name:
            NameFull: Schmid DE
      – PersonEntity:
          Name:
            NameFull: Borgna F
      – PersonEntity:
          Name:
            NameFull: Fani M
      – PersonEntity:
          Name:
            NameFull: Bernhardt P
      – PersonEntity:
          Name:
            NameFull: van der Meulen NP
      – PersonEntity:
          Name:
            NameFull: Müller C
      – PersonEntity:
          Name:
            NameFull: Schibli R
      – PersonEntity:
          Name:
            NameFull: Wild D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 03
              Text: 2026 Mar 02
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1535-5667
          Numbering:
            – Type: volume
              Value: 67
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
              Type: main
ResultId 1